Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer

被引：7
作者：
Caine, GJ
Harris, AL
Christodoulos, K
Lip, GYH
Blann, AD [1 ]
机构：
[1] Univ Dept Med, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
[2] Churchill Hosp, Canc Res UK, Med Oncol Unit, Oxford OX3 7LJ, England
来源：
CANCER LETTERS | 2005年 / 219卷 / 02期
关键词：
angiogenesis; platelets; soluble P-selectin; tissue factor; VEGF;
D O I：
10.1016/j.canlet.2004.09.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P < 0.001) and TF (P < 0.001), but not VEGF (P = 0.066) than 25 age and sex-matched controls. VEGF and TF correlated significantly (r = 0.8, P < 0.001) in cancer patients. Soluble P-selectin, TF and VEGF did not change at 4- and 8-weeks whilst on treatment. We provide further evidence linking coagulation and angiogenesis but combination anti-angiogenesis therapy does not influence plasma soluble P-selectin,TF or VEGF. (c) 2004 Published by Elsevier Ireland Ltd.
引用
收藏
页码：163 / 167
页数：5
相关论文
共 32 条
  • [11] ANGIOGENESIS INHIBITION AND TUMOR-REGRESSION CAUSED BY HEPARIN OR A HEPARIN FRAGMENT IN THE PRESENCE OF CORTISONE
    FOLKMAN, J
    LANGER, R
    LINHARDT, RJ
    HAUDENSCHILD, C
    TAYLOR, S
    [J]. SCIENCE, 1983, 221 (4612) : 719 - 725
  • [12] Tissue specific expression and serum levels of human tissue factor in patients with urological cancer
    Förster, Y
    Meye, A
    Albrecht, S
    Kotzsch, M
    Füssel, S
    Wirth, MP
    Schwenzer, B
    [J]. CANCER LETTERS, 2003, 193 (01) : 65 - 73
  • [13] Soluble P-selectin is influenced by cancer chemotherapy
    Gurney, D
    Poole, C
    Kehoe, S
    Lip, GYH
    Blann, AD
    [J]. PLATELETS, 2001, 12 (01) : 37 - 38
  • [14] Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma
    Hii, SI
    Nicol, DL
    Gotley, DC
    Thompson, LC
    Green, MK
    Jonsson, JR
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (06) : 880 - 883
  • [15] Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients
    Kuenen, BC
    Levi, M
    Meijers, JCM
    Kakkar, AK
    van Hinsbergh, VWM
    Kostense, PJ
    Pinedo, HM
    Hoekman, K
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (09) : 1500 - 1505
  • [16] Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer
    Lin, SY
    Wang, YY
    Sheu, WHH
    [J]. CLINICAL ENDOCRINOLOGY, 2003, 58 (04) : 513 - 518
  • [17] Cancer and the prothrombotic state
    Lip, GYH
    Chin, BSP
    Blann, AD
    [J]. LANCET ONCOLOGY, 2002, 3 (01) : 27 - 34
  • [18] Macaulay VM, 1999, CLIN CANCER RES, V5, P513
  • [19] Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets
    Müller, I
    Klocke, A
    Alex, M
    Kotzsch, M
    Luther, T
    Morgenstern, E
    Zieseniss, S
    Zahler, S
    Preissner, K
    Engelmann, B
    [J]. FASEB JOURNAL, 2003, 17 (01) : 476 - +
  • [20] Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer
    Nakasaki, T
    Wada, H
    Shigemori, C
    Miki, C
    Gabazza, EC
    Nobori, T
    Nakamura, S
    Shiku, H
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2002, 69 (04) : 247 - 254
1234